share_log

Decoding 10 Analyst Evaluations For CG Oncology

Benzinga ·  May 15 01:00

In the latest quarter, 10 analysts provided ratings for CG Oncology (NASDAQ:CGON), showcasing a mix of bullish and bearish perspectives.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings54100
Last 30D10000
1M Ago32000
2M Ago10000
3M Ago02100

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $64.7, with a high estimate of $75.00 and a low estimate of $42.00. Marking an increase of 50.47%, the current average surpasses the previous average price target of $43.00.

price target chart

Exploring Analyst Ratings: An In-Depth Overview

A comprehensive examination of how financial experts perceive CG...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment